Novo Nordisk A/S (NVO) News

Novo Nordisk A/S (NVO): $111.64

0.21 (+0.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter NVO News Items

NVO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVO News Highlights

  • For NVO, its 30 day story count is now at 53.
  • Over the past 24 days, the trend for NVO's stories per day has been choppy and unclear. It has oscillated between 1 and 23.
  • The most mentioned tickers in articles about NVO are TOUR, DE and RACE.

Latest NVO News From Around the Web

Below are the latest news stories about Novo Nordisk A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.

Top Stock Reports for Procter & Gamble, Chevron & Novo Nordisk

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Chevron Corporation (CVX), and Novo Nordisk A/S (NVO).

Yahoo | February 25, 2022

Check Out What Whales Are Doing With NVO

Someone with a lot of money to spend has taken a bearish stance on Novo Nordisk (NYSE: NVO ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with NVO, it often means somebody knows something is about to happen. Today, Benzinga ''s options scanner spotted 26 options trades for Novo Nordisk . This isn''t normal. The overall sentiment of these big-money traders is split between 19% bullish and 80%, bearish. Out of all of the options we uncovered, there was 1 put, for a total amount of $35,000, and 25, calls, … Full story available on Benzinga.com

Benzinga | February 24, 2022

Novo Nordisk – major shareholder announcement

Bagsværd, Denmark, 21 February 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) as follows: Blackrock holds as of 15 February 2022 B shares equal to 4.98% of the entire share capital of Novo Nordisk. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)

Yahoo | February 21, 2022

Notice for the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 21 February 2022 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 24 March 2022 at 14.00 (CET) The Annual General Meeting is held as a partially electronic general meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark or participating virtually via an IT application. We encourage shareholders to exercise their rights by submitting proxies or votes by corresponde

Yahoo | February 21, 2022

Novo Nordisk A/S: Share repurchase programme

Bagsværd, Denmark, 21 February 2022 – On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 22 billion to be executed during a 12-month period beginning 2 February 2022. Under the programm

Yahoo | February 21, 2022

Centre for type 1 diabetes patients at GIMS soon

The Government Institute of Medical Sciences (GIMS) has signed a memorandum of understanding (MOU) with pharmaceutical company Novo Nordisk to develop a centre of excellence for extending medical care, including education, support, evaluation, and insulin, to children with type 1 diabetes in

The Times of India | February 18, 2022

Prothena (PRTA) Q4 Earnings Beat, Pipeline Progress in Focus

Prothena beats on earnings and revenues in the fourth quarter of 2021. The company's progress with its AD pipeline is encouraging.

Yahoo | February 18, 2022

2022 TOUR DE POLOGNE WILD CARDS: The first one goes to Team Novo Nordisk

ATLANTA , Feb. 11, 2022 /PRNewswire-PRWeb/ -- Team Novo Nordisk and Tour de Pologne, plenty of inspiring stories. The first wild card for the 79th edition of Tour de Pologne goes to Team Novo Nordisk, a team which characterizes the World Tour panorama for its special mission. One such story features 28-year-old Frenchman Charles Planet . He has lived with type 1 diabetes since the age of 10 and in 2019, he proved himself at the Tour de Pologne. On the opening stage to Krakow, he won the Best Climber jersey, which he kept until stage five and the day after, he got the Most Active Rider jersey, which he wore until the end of the Tour. "It''s no secret that I achieved my greatest success at the Tour de Pologne in 2019," explains Charles. "I have good memories of winning the Most Active Rid...

Benzinga | February 11, 2022

Novo Nordisk: Solid Q4 Results, Company Likely To Continue Growth Trajectory

No summary available.

Seeking Alpha | February 11, 2022

Trading in Novo Nordisk shares by board members, executives and associated persons on 8 February 2022

Trading in Novo Nordisk shares by board members, executives and associated persons on 8 February 2022 Bagsværd, Denmark, 11 February 2022 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to p

Yahoo | February 11, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4879 seconds.